Navigation Links
Intradigm Closes Final Tranche of $21.4 Million Series B Financing
Date:1/7/2009

amie Topper, M.D., Ph.D., the chairman of the board of Intradigm. "At the same time, we are excited to have Dr. Haworth assume the role of CEO and apply his impressive breadth of industry experience to the continued success of the company."

Dr. Haworth possesses more than 15 years of management experience in the biotechnology industry. He has previously held senior executive roles at several leading biotechnology companies including Genencor International and COR Therapeutics, among others. In these positions, he led the identification and negotiation of numerous collaborative and licensing agreements with a range of global and regional pharmaceutical companies. He possesses deep operational expertise that spans discovery and development, technology and product licensing, mergers and acquisitions, and financings.

"I am pleased to have the opportunity to support Intradigm's exceptional team as we work to further strengthen the company's position of leadership in the RNAi sector," said Dr. Haworth. "Astellas' decision to join our experienced investor base, as well as Lilly Ventures' desire to increase its investment, provides additional support and validation for Intradigm and our ongoing development efforts in the promising area of RNAi."

ABOUT INTRADIGM

Intradigm is a private biotechnology company committed to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases with an initial focus on oncology. Intradigm is unique among private companies, with its comprehensive RNAi therapeutics platform consisting of structural features for next-generation RNAi molecules, biodegradable polycationic polymers for the delivery of RNAi therapeutics and proprietary siRNA sequence applications. Our proprietary delivery technology is unique in its potential to offer safe and effective systemic administration using a lib
'/>"/>

SOURCE Intradigm Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Intradigm Licenses Key Next Generation RNA Interference (RNAi) Intellectual Property From University of Massachusetts Medical School
2. Intradigm Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency of RNAi Therapeutics
3. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
4. Genmab Discloses Target and Development Plans for HuMax-Inflam
5. Oxford Finance Corporation Closes $7 Million Debt Facility with Othera Pharmaceuticals
6. RoundTable Healthcare Partners Closes Sale of MedAssist Holding, Inc. to Firstsource Solutions Limited
7. Gilde Healthcare Partners Closes EUR 150 Million European Healthcare Venture Fund
8. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
9. BioVex Closes Second Round of Series E Financing
10. Pharmaxis Closes Share Purchase Plan
11. The closest look ever at native human tissue

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)...SEATTLE, Nov. 19 Omeros ...ited financial results for the third quarter ended...ptember 30, 2009, Omeros reported a net loss of $3...et loss of $7.4 million, or $2.54 per share, for t...September 30, 2009, the Company reported a net los...
(Date:11/19/2009)..., ,, BETHESDA, Md., Nov. 19 /PRNewswire-Fir...an innovator in biotechnology for diabetes therapy...lting services to food, supplement, biotechnology ...losed the previously reported $6.3 million registe... 2,760,870 shares of its common stock and warrants...
(Date:11/19/2009)...BETHESDA, Md., Nov. 19 S... in biotechnology for diabetes therapy, and a prov...es to food, supplement, biotechnology and pharmace...uesday,s Annual Meeting of Shareholders. ,, At ...(Nasdaq: SPEX ) elected the following members to ...
(Date:11/19/2009)..., MUNSTER, Germany, November 19 /PRNewswire/ ...filed on November 16th, 2009 Flibanserin in the,in...nesia in Parkinson,s,disease for orphan drug statu...EMEA). Levodopa-induced dyskinesia is a complicati...,s and a serious burden to some of those,affected,...
Breaking Biology Technology:Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8Spherix Announces the Closing of $6.3 Million Registered Direct Offering 2Spherix Announces the Closing of $6.3 Million Registered Direct Offering 3Spherix Announces Results of Annual Shareholders Meeting 2Spherix Announces Results of Annual Shareholders Meeting 3Spherix Announces Results of Annual Shareholders Meeting 4MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as "Orphan Drug" 2
... Time -, SAN FRANCISCO, Nov. 10 Medivation, Inc....progress and financial,results for the quarter end...ented another quarter of significant,achievement a... partnering,agreement with Pfizer for Dimebon. Thi...d-class partner capable of maximizing global,comme...
... Discuss the Data and Ongoing ...Nov. 10 Sangamo,BioSciences, Inc. (Nasdaq: SGMO ...1 clinical trial, one of Sangamo,s three Phase 2 c...am to develop SB-509 for diabetic,neuropathy (DN)....f the,drug is well tolerated in subjects with mild...
...es of Non-Core Product Lines -, HOPKINTON, Mass.,...LP ) today reported third quarter financial,result...divestitures: the,sale of its AutoTrace(R) product...he sale of its Pharmaceutical Development and Qual...on for $15.8 million. Revenues for the,quarter wer...
Other Biology Technology:Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 2Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 3Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 4Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 5Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 6Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 7Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 8Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 2Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 3Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 4Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 5Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 6Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 2Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 3Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 4Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 5Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 6Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 7Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 8Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 9Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 10Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 11
(Date:11/23/2009)... Current research suggests that a common oral bact...ted report by Nichols et al, "Unique Lipids from a...LR2 Ligands Capable of Enhancing Autoimmunity," ap...Journal of Pathology . , Multiple sclerosis (MS)...ain and spinal cord, affects nearly 1 in 700 peopl...
(Date:11/23/2009)...The only swine vaccine available for the H1N1 viru... with the virus. The vaccination marks the first t...d with the pandemic flu., Iowa State University,...ped the vaccine this summer and has been shipping ...s and Illinois for several weeks., The latest va...
(Date:11/23/2009)...vember 16, 2009 -- A USDOE and USDA study conclude...pland, and cropland pasture could be converted fro...ses, such as switchgrass, from which biomass could...omically viable production of a perennial grass mo...mass are removed annually is expected to require n...
Breaking Biology News(10 mins):Factors from common human bacteria may trigger multiple sclerosis 2Iowa State researcher produces, ships only H1N1 vaccine available for swine 2Switchgrass produces biomass efficiently 2UK Identity and Passport Service and IBM Sign 7 year National Biometric Identity Service 28NBIS 29 Contract 9215 1UK Identity and Passport Service and IBM Sign 7 year National Biometric Identity Service 28NBIS 29 Contract 9215 2Obama 3A Too Many Still Die from Diseases That Shouldnt Kill Them 51397 1Obama 3A Too Many Still Die from Diseases That Shouldnt Kill Them 51397 2Mayo Clinic Study Using Structural MRI May Help Accurately Diagnose Dementia Patients 51392 1Mayo Clinic Study Using Structural MRI May Help Accurately Diagnose Dementia Patients 51392 2
...h, and still the University of Wisconsin-Madison S...requests. Since 1998, the school,s oncology depar...r dogs diagnosed with melanoma. Though it is sti...over the nation have wanted to participate in the ...heir pet. , After promising results from work done...
...we carry this activity out through the placenta an...velopment, the lungs of the foetus are filled with... activates this respiration surface. But the main ...ungs are not well formed. Moreover, they often lac...pids that avoids the lungs folding in on themselve...
...billion-base human genome play a vital role in a b...chers from the Wellcome Trust Sanger Institute and...r Medical Research, together with international co...ps of differences implicated in disease as well as... , The Major Histocompatibility Complex (MHC) con...
Other Biology News:Canine cancer vaccine program shows early promise 2Liquid ventilation 2Researchers map of genetic variations implicated in disease 2Researchers map of genetic variations implicated in disease 3
...ein Phosphatase-2A (PPase-2A) is a serine/threonin... It is isolated as the heterodimer of 60kDa (A) an...phorylate the a-subunit of phosphorylase kinase. W...oad substrate specificity and may play a regulator...
...oskan is a high performance spectral scanning mult.... With the advanced SkanIt Software it offers supe...y assay development. Varioskan provides unlimited ...ime-resolved fluorescence and photometric assays a...
...ctively condenses and traps a wide variety of solv... pump oil. Easy-to-use glass condensation flask (G...self contained jar for easy draining. Rapid coolin...4 o C temperature traps high volatile solvents ...
Immulon 2HB from Thermo Scientific
Biology Products: